Global Bill Timeline

15 Oct 2026 · Transferred to Senate Law and Public Safety.

CJ’s Law (2026–2027)

22 Sep 2026 · Referred to Senate Regulatory Affairs.

Kratom Consumer Protection Act (2025–2026)

10 Sep 2026 · Referred to Assembly Judiciary.

7-hydroxymitragynine scheduling (2026–2027)

8 Sep 2026 · Signed; effective the same day.

Kratom Consumer Protection Act — enacted substitute (2026)

3 Sep 2026 · Referred to House Energy and Commerce and Judiciary.

End Gas Station Heroin Act (119th Congress (2025–2026))

13 Aug 2026 · August 13 hearing: Held in committee and under submission.

The California Emerging Therapies Research Partnership Act. (2026 Session)

10 Aug 2026 · Accompanied new draft S3198.

An Act concerning the regulation of Kratom (2025–2026)

8 Aug 2026 · Read twice; referred to Senate Judiciary.

End Gas Station Heroin Act (119th Congress (2025–2026))

1 Aug 2026 · Effective date 8/1/2026.

Provides relative to psychedelic-assisted therapy (2026 Regular Session)

23 Jul 2026 · Referred

An Act authorizing a pilot for the use of psychedelics in licensed treatment facilities (194th General Court (2025–2026))

23 Jul 2026 · Referred to House Energy and Commerce and Ways and Means.

Safe Sips Act of 2026 (119th Congress (2025–2026))

22 Jul 2026 · Referred

Establishing a pilot program for access to regulated psilocybin (2026 Session)

20 Jul 2026 · Signed into Law

Relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact. (2026 Regular Session)

17 Jul 2026 · Referred

IBOGAINE Act (119th Congress)

9 Jul 2026 · Reporting date extended to Thursday, December 31, 2026

Relative to therapeutic psilocybin treatment centers (2026 Session)

22 Jun 2026 · Passed

approved medications; scheduling; prescription authority (2026 Regular Session)

17 Jun 2026 · Hearing canceled at author’s request.

Public health: kratom (2025–2026)

13 Jun 2026 · Assigned to House RULES Committee

Mescaline; possession; sale; commercial use (2026 Session)

11 Jun 2026 · Replaced by HS1 for HB332.

Kratom Consumer Protection Act (2026)

10 Jun 2026 · Re-referred to House Regulatory Reform.

Kratom product regulation (2025–2026)

9 Jun 2026 · Committee Report

Health: research; participation in ibogaine clinical trials; provide for (2025–2026 Regular Session)

5 Jun 2026 · Passed Assembly and returned to Senate.

7-OH product restrictions (2025–2026)

4 Jun 2026 · Passed

Natural Medicine (2026 Regular Session)

4 Jun 2026 · Passed

An Act Concerning the Psychedelic-Assisted Therapy Pilot Program (2026 February Session)

27 May 2026 · Assigned Public Chapter 1119

Relative to clinical trials (114th General Assembly (2025-2026))

27 May 2026 · Signed into Law

AN ACT to amend Tennessee Code Annotated, Title 9; Title 33; Title 53; Title 63 and Title 68, relative to clinical trials. (2026 Session)

15 May 2026 · Referred

Psilocybin Advisory Board (104th General Assembly (2025–2026))

14 May 2026 · In committee: Held under submission.

Controlled substances: research. (2026 Session)

12 May 2026 · Signed into Law

Medical Practice Act; regulation of the administration of psychedelic-assisted treatment and therapy; provide (2025–2026 Regular Session)

12 May 2026 · Passed

Oklahoma Breakthrough Therapy Act (2026 Regular Session)

11 May 2026 · Signed into Law

Controlled substances; Schedule I; psilocybin; revise a provision (2026 Session)

8 May 2026 · print number 2142a

Allows the growth, cultivation, and adult use of psilocybin for the treatment of certain health conditions (2025-2026 Legislative Session)

8 May 2026 · PRINT NUMBER 5303A

Allows the growth, cultivation, and adult use of psilocybin for the treatment of certain health conditions (2025-2026 Legislative Session)

7 May 2026 · Referred

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2026 Session)

7 May 2026 · Placed Back on Formal Perfection Calendar (H)

Creates provisions relating to ibogaine treatment (2026 Session)

7 May 2026 · Committee Report

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2026 Session)

7 May 2026 · Inexpedient to Legislate, Motion Adopted, Voice Vote === BILL KILLED ===; 05/07/2026; Senate Journal 11

Authorizing the medical use of psilocybin through a program established in the department of health and human services. (2026 Session)

5 May 2026 · Referred

The HEAL Act. (2025-2026 Session)

1 May 2026 · Amendment S-5248 filed. S.J. 960.

A bill for an act relating to the production and administration of psilocybin, and providing penalties. (Formerly HF 620.) (2026 Session)

29 Apr 2026 · Conference committee meeting to reconvene on 05-01-26 3:15PM; Conference Room 329.

Relating To Mental Health. (2026 Session)

29 Apr 2026 · Committee Report

Requires the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction. (2026 Session)

28 Apr 2026 · Signed into Law

Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership (2026 Regular Session)

28 Apr 2026 · Signed into Law

Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership (2026 Session)

27 Apr 2026 · Amendment S-5215 filed.

Designating kratom as a Schedule I controlled substance (2026)

22 Apr 2026 · Author added Rymer

Psilocybin therapeutic use program established; protections for registered patients, designated cultivators, registered facilitators, and health care practitioners established; rulemaking authorized; civil actions authorized; fees established; advisory committee established; criminal penalties provided; and money appropriated. (2026 Session)

20 Apr 2026 · Passed

Use of Prescription Product with Controlled Substance (2026 Session)

20 Apr 2026 · Author added Seeberger

Psilocybin therapeutic use program establishment (2026 Session)

16 Apr 2026 · Referred

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2026 Session)

15 Apr 2026 · Replaced by SS1 for SB262.

Uniform Controlled Substances Act amendments (2026)

14 Apr 2026 · Referred

An Act relating to ibogaine research in the Commonwealth (2026 Regular Session)

13 Apr 2026 · Signed into Law

Relating to health care; and declaring an emergency. (2026 Session)

9 Apr 2026 · Motion to recall and re-refer, motion prevailed Veterans and Military Affairs Division

Psilocybin therapeutic use program established; protections for registered patients, registered suppliers, registered facilitators, and health care practitioners established; civil actions authorized; advisory committee established; and money appropriated. (2026 Session)

9 Apr 2026 · Withdrawn at sponsor's request

Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the US FDA's program, mandate that RI department of health establish rules regulations. (2026 Session)

6 Apr 2026 · Signed into Law

Board of Pharmacy; regulation of psilocybin. (2026 Regular Session)

6 Apr 2026 · Signed into Law

Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes. (2026 Session)

2 Apr 2026 · Received notice of the discharge of all House Conferees (Hse. Com. No. 457).

Relating To Mental Health. (2026 Session)

2 Apr 2026 · Accompanied a study order, see H5318

To amend the General Laws, in relation to promoting the health and well-being of the residents of the Commonwealth of Massachusetts by establishing a comprehensive framework supporting public health and safety through regulated adult use, support services, and cultivation of psilocybin-containing fungi; and providing for taxation and appropriation thereof (2026 Session)

1 Apr 2026 · Voted Do Pass S Veterans and Military Affairs Committee

Establishes the "Veterans Mental Health Innovation Act" relating to ibogaine treatment (2026 Session)

1 Apr 2026 · Vetoed by Governor 4/1/2026 - House Journal

Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine (2026 Session)

27 Mar 2026 · Referred

USE AND RESEARCH-ENTHEOGENS (2026 Session)

27 Mar 2026 · Referred

HOPE PILOT PROGRAM (2026 Session)

27 Mar 2026 · Referred

Illinois CURE Act (an act concerning health) (104th General Assembly (2025–2026))

27 Mar 2026 · Approved by Governor 3/27/2026 - Senate Journal

Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations (2026 Regular Session)

26 Mar 2026 · Accompanied a study order, see H5281 (under House Rule 27)

Relative to criminal disposition of limited psilocybin possession offenses (2026 Session)

26 Mar 2026 · Accompanied a study order, see H5281 (under House Rule 27)

Establishing a task force to study equitable access to psilocybin and other entheogenic plants (2026 Session)

26 Mar 2026 · Accompanied a study order, see H5281 (under House Rule 27)

Relative to removing criminal penalties for limited psilocybin possession (2026 Session)

26 Mar 2026 · Passed

Ibogaine; authorize SDH to select a consortium to conduct a drug development clinical trial with, to secure FDA's approval of. (2026 Session)

25 Mar 2026 · Referred

"Veterans Mental Health Innovations Act"; enact (2026 Session)

24 Mar 2026 · Passed

Controlled Substance Scheduling Amendments (2026 General Session)

23 Mar 2026 · Laid on table under Senate Rule 9.

Kratom product regulation (2025–2026)

19 Mar 2026 · Referred

Urging The Convening Of A Mental Health Emerging Therapies Task Force To Prepare The State For The Integration Of Breakthrough Therapies And To Explore Opportunities To Expand Clinical Trials, Research Partnerships, And Treatment Capacity In The State. (2026 Session)

19 Mar 2026 · Referred

Urging The Convening Of A Mental Health Emerging Therapies Task Force To Prepare The State For The Integration Of Breakthrough Therapies And To Explore Opportunities To Expand Clinical Trials, Research Partnerships, And Treatment Capacity In The State. (2026 Session)

19 Mar 2026 · Referred to House Energy and Commerce and Judiciary.

END 7-OH Act (119th Congress (2025–2026))

19 Mar 2026 · Passed

Veterans PTSD Clinical Research Amendments (2026 Session)

17 Mar 2026 · Introduced

Psilocybin therapeutic use program establishment (2026 Session)

16 Mar 2026 · Introduced

Adds to existing law to establish the Medical Advanced Healing Act. (2026 Session)

16 Mar 2026 · Reported favorably; referred to Senate Budget and Appropriations.

7-hydroxymitragynine scheduling (2026–2027)

13 Mar 2026 · Passed

Controlled substances; provide for automatic scheduling of certain substance if federal scheduling occurs. (2026 Session)

11 Mar 2026 · Failed

Controlled substances; provide for automatic scheduling of psilocybin after federal scheduling. (2026 Session)

10 Mar 2026 · Passed

An Act to reschedule crystalline polymorph psilocybin in an FDA-approved drug product as a Schedule IV controlled substance (2026 Regular Session)

9 Mar 2026 · Laid on Table, refer to CS/SB 432

Controlled Substances (2026 Session)

9 Mar 2026 · Introduced

Psilocybin regulation provisions (2026 Session)

9 Mar 2026 · Introduced

Innovative Therapies Centers of Excellence Act (119th Congress)

6 Mar 2026 · Referred

Mental health; pilot program to support clinical research of certain veterans and first responders suffering from certain conditions; provide (2026 Session)

6 Mar 2026 · Failed

Relating to ibogaine; prescribing an effective date. (2026 Session)

6 Mar 2026 · Failed

Controlled Substances Amendments (2026 Session)

27 Feb 2026 · Introduced

Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the Food and Drug Administration (FDA) program, mandates that RI DOH establishes rules regulations. (2026 Session)

26 Feb 2026 · Introduced

Controlled substances: conduct associated with qualified psychoactive substances exempt from criminal penalties in certain circumstances (2025–2026 Regular Session)

26 Feb 2026 · Committee Report

Creates provisions relating to ibogaine treatment (2026 Session)

26 Feb 2026 · Committee Report

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2026 Session)

19 Feb 2026 · House Stricken from Calendar by Rule 1507

Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act. (2026 Session)

19 Feb 2026 · Referred to Assembly Consumer Affairs.

Kratom consumer protection (2026–2027)

18 Feb 2026 · Committee Report

Controlled substances; approval; use; research (2026 Session)

16 Feb 2026 · Introduced

Establish a regulated framework for the medical use of psilocybin to treat post-traumatic stress disorder (PTSD) (2026 Session)

13 Feb 2026 · Introduced

Public Health - Ibogaine Clinical Research Grant Program - Establishment (Veterans Mental Health Innovations Act) (2026 Session)

10 Feb 2026 · Referred

Controlled dangerous substances; Veterans Mental Health Innovation Act; authorizing certain scientific research and clinical trials related to ibogaine; requiring registration; providing certain immunities; effective date. (2026 Session)

10 Feb 2026 · Introduced and referred to Senate Judiciary.

Kratom product regulation (2026)

9 Feb 2026 · Hearing 2/24 at 1:00 p.m.

Public Health - Ibogaine Clinical Research Grant Program - Establishment (Veterans Mental Health Innovations Act) (2026 Session)

5 Feb 2026 · Subcommittee: Sweeney, Donahue, and Webster. S.J. 214.

A bill for an act removing psilocybin and psilocyn from the list of substances classified as schedule I controlled substances under Iowa's uniform controlled substances Act. (2026 Session)

4 Feb 2026 · Introduced

Use Of Fda-approved Psilocybin (2026 Session)

4 Feb 2026 · Referred

Concerning psilocybin. (2026 Session)

3 Feb 2026 · Failed

Mississippi Veterans PTSD Ibogaine Research Pilot Program; create. (2026 Session)

3 Feb 2026 · Failed

Ibogaine; authorize MSDH to select a consortium to conduct a drug development clinical trial to secure FDA's approval of. (2026 Session)

3 Feb 2026 · In Committee

Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions. (2026 Session)

3 Feb 2026 · Introduced

An act relating to psychedelic therapy and clinical drug development trials (2026 Session)

2 Feb 2026 · Failed

Veterans and Former First Responders Research Pilot Program. (2026 Session)

2 Feb 2026 · Referred

Expanding Veterans’ Access to Emerging Treatments Act (2026 Session)

2 Feb 2026 · On 1st reading, House Calendar

Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration (2026 Session)

29 Jan 2026 · Accompanied a study order, see S2930

Relative to removing criminal penalties for limited psilocybin possession (2026 Session)

28 Jan 2026 · Accompanied a new draft, see H4986

Decriminalizing psilocybin as a treatment for PTSD and certain other conditions (2026 Session)

28 Jan 2026 · Accompanied a new draft, see H4986

Relative to therapeutic psilocybin treatment centers (2026 Session)

26 Jan 2026 · Subcommittee Meeting: 01/26/2026 12:15PM RM 305 (Cancelled).

A bill for an act relating to the production and administration of psilocybin and providing penalties. (2026 Session)

23 Jan 2026 · Introduced

Amending The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control (2025-2026 Regular Session)

22 Jan 2026 · Introduced

Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration (2026 Session)

21 Jan 2026 · Introduced

Establishes a research grant program to fund clinical trials of ibogaine for the treatment of veterans for post-traumatic stress disorder; creates a fund to provide monies for the research grant program. (2026 Session)

20 Jan 2026 · Signed into Law

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million. (2024-2025 Legislative Session)

13 Jan 2026 · Introduced

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness. (2026 Session)

13 Jan 2026 · Introduced

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million. (2026 Session)

13 Jan 2026 · Referred to Senate Commerce.

Kratom Consumer Protection Act (2026–2027)

13 Jan 2026 · Referred to Assembly Judiciary.

CJ’s Law (2026–2027)

13 Jan 2026 · Referred to Assembly Consumer Affairs.

CJ’s Law — kratom restrictions (2026–2027)

12 Jan 2026 · Substituted by S2283 (SCS/2R)

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million. (2026 Session)

12 Jan 2026 · By resolution, reintroduced and retained in present status.

Concerning access to psychedelic substances. (2026 Session)

12 Jan 2026 · By resolution, reintroduced and retained in present status.

Concerning access to psychedelic substances. (2026 Session)

12 Jan 2026 · By resolution, reintroduced and retained in present status.

Concerning ibogaine-assisted therapy. (2026 Session)

9 Jan 2026 · PRINT NUMBER 1801A

Establishes the psilocybin assisted therapy pilot program; provides such program will be offered to veterans and first responders from New York state; establishes a psilocybin assisted therapy pilot program fund. (2026 Session)

8 Jan 2026 · print number 3845a

Establishes the psilocybin assisted therapy pilot program; provides such program will be offered to veterans and first responders from New York state; establishes a psilocybin assisted therapy pilot program fund. (2026 Session)

7 Jan 2026 · Session start

Designate certain substances as controlled substances under the Uniform Controlled Substances Act (109th Legislature, Second Session (2026))

7 Jan 2026 · Referred

Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor. (2026 Session)

7 Jan 2026 · Referred

Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor. (2026 Session)

7 Jan 2026 · Referred

Directs the commissioner of health, in conjunction with the commissioners of mental health and veterans' services, to conduct a study on the use of ibogaine as a treatment for post-traumatic stress disorder, and the increasing rate of PTSD diagnoses in veterans and first responders. (2026 Session)

7 Jan 2026 · Referred

Requires the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction. (2026 Session)

7 Jan 2026 · Referred

Legalizes adult possession and use of certain natural plant or fungus-based hallucinogens; grants certain protections for individuals lawfully using such hallucinogens; removes such hallucinogens from the list of schedule I controlled substances; makes related provisions. (2026 Session)

8 Dec 2025 · Carried over to 2026; session has since ended.

Hawaii Kratom Consumer Protection Act (2025–2026)

19 Nov 2025 · Referred to House Health.

Kratom product regulation (2025–2026)

10 Oct 2025 · Signed into Law

Controlled substances: research. (2025–2026 Regular Session)

2 Oct 2025 · Referred

Authorizing a pilot for the use of psychedelics in licensed treatment facilities (2025 Session)

11 Jul 2025 · Act 35 became effective.

South Carolina Kratom Consumer Protection Act (2025–2026)

25 Jun 2025 · Introduced

Crimes: controlled substances; creating, manufacturing, possessing, or using psilocybin or psilocin; allow under certain circumstances. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7404a. (2025 Session)

11 Jun 2025 · Passed

Appropriations act including crystalline polymorph psilocybin provisions (91st General Assembly (2025–2026))

11 Jun 2025 · Vetoed

A bill for an act relating to the controlled substance crystalline polymorph psilocybin. (Formerly HF 14.) Vetoed 6-11-25. (2025 Session)

11 Jun 2025 · Passed

Relating to the establishment of a consortium to conduct FDA drug development clinical trials with ibogaine (2025 Regular Session (89th Legislature))

10 Jun 2025 · Failed

An Act to Decriminalize Personal Possession of Therapeutic Amounts of Psilocybin for Adults (2025 Session)

5 Jun 2025 · Pending Motion Committee Amendment # 2025-2167s; 06/05/2025; Senate Calendar 25

Amending the penalties for the possession and use of psilocybin for persons 18 years of age or older. (2025 Session)

3 Jun 2025 · Failed

Creates the Alternative Therapy Pilot Program. (BDR 40-820) (2025 Session)

1 Jun 2025 · Enrolled (Passed Both Chambers)

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (2025 Regular Session)

20 May 2025 · Committee Report

An Act Concerning The Decriminalization Of Possession Of Small Amounts Of Psilocybin. (2025 Session)

19 May 2025 · Referred

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions. (2025 Session)

15 May 2025 · Referred

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2025 Session)

14 May 2025 · Introduced

A bill for an act relating to state government and finances, including by making, modifying, limiting, or reducing appropriations, distributions, or transfers, authorizing expenditure of unappropriated moneys in special funds, providing for properly related matters including crystalline polymorph psilocybin and medical residency and fellowship positions, making corrections, and including effective date and retroactive applicability provisions.(See SF 659.) (2025 Session)

13 May 2025 · Referred

Relating to the scheduling of certain controlled substances in response to certain actions by the United States Food and Drug Administration with respect to those substances. (2025 Session)

12 May 2025 · Introduced

Amending The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control (2025-2026 Regular Session)

12 May 2025 · Laid on the table subject to call

Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy. (2025 Session)

8 May 2025 · Referred

Innovative Therapies Centers of Excellence Act of 2025 (2025 Session)

6 May 2025 · Dropped from Calendar - Pursuant to House Rules (H)

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2025 Session)

29 Apr 2025 · Co-author authorized

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions. (2025 Session)

28 Apr 2025 · Withdrawn. H.J. 1073.

A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(See HF 978.) (2025 Session)

11 Apr 2025 · Laid over on 3rd reading 4/11/2025

Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine (2025 Session)

7 Apr 2025 · Signed into Law

Medical Psilocybin Act (2025 Regular Session)

2 Apr 2025 · Senate sustained Governor's veto

Crystalline polymorph psilocybin; regulations for prescribing, etc. (2025 Session)

31 Mar 2025 · Passed

FDA-Approved Crystalline Polymorph Psilocybin Use (2025 Session)

27 Mar 2025 · Filed with Secretary Of State 03/26

Relating to the scheduling of controlled substances (2025 Regular Session)

27 Mar 2025 · Referred

Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration (2025 Session)

26 Mar 2025 · Referred

Innovative Treatments for Mental Health Act (2025 Session)

24 Mar 2025 · Introduced

Psilocybin cultivation, possession, transportation, and personal use by individuals 21 years of age or older authorized; protections established; public education and harm reduction programs established; Psychedelic Medicine Board established; criminal penalties provided; rulemaking authorized; civil actions authorized; and money appropriated. (2025 Session)

21 Mar 2025 · Rule 19(a): re-referred to Rules Committee.

Illinois Kratom Consumer Protection Act (2025–2026)

14 Mar 2025 · Introduced

Study Psilocybin-based Medication Treatment (2025 Session)

12 Mar 2025 · SCS Voted Do Pass S Families, Seniors and Health Committee (1343S.02C)

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2025 Session)

11 Mar 2025 · Introduced

An act relating to continuing the Psychedelic Therapy Advisory Working Group (2025 Session)

28 Feb 2025 · Introduced

An act relating to decriminalization of psilocybin-containing mushrooms and the establishment of the Psilocybin Therapeutic Consultation Program (2025 Session)

26 Feb 2025 · Introduced

A bill for an act relating to the use of certain psychoactive substances under the religious freedom restoration Act. (2025 Session)

26 Feb 2025 · Passed

Change provisions relating to controlled substances schedules under the Uniform Controlled Substances Act (2025 Session)

24 Feb 2025 · Withdrawn. H.J. 418.

A bill for an act relating to the controlled substance crystalline polymorph psilocybin.(See HF 383.) (2025 Session)

24 Feb 2025 · Introduced

A bill for an act relating to the controlled substance crystalline polymorph psilocybin. (2025 Session)

20 Feb 2025 · Referred

AN ACT relating to Ibogaine research in the Commonwealth. (2025 Session)

19 Feb 2025 · Tabled Indefinitely, Bill Has Died

Crystalline Polymorph Psilocybin Rescheduling (2025 Session)

12 Feb 2025 · Introduced

A bill for an act removing psilocybin and psilocyn from the list of substances classified as schedule I controlled substances under Iowa's uniform controlled substances Act. (2025 Session)

11 Feb 2025 · Committee recommended measure be held for further study

Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the US FDA's program, mandate that RI department of health establish rules regulations. (2025 Session)

4 Feb 2025 · Referred to Health and Human Services.

Kratom Consumer Protection Act (2025–2026)

23 Jan 2025 · Introduced

An Act Decriminalizing The Possession Of Psilocybin. (2025 Session)

22 Jan 2025 · Introduced

An Act Concerning Funding For The Psychedelic-assisted Therapy Pilot Program. (2025 Session)

17 Jan 2025 · Introduced

An Act Allowing The Use Of Psilocybin For Medicinal And Therapeutic Purposes. (2025 Session)

7 Jan 2025 · Failed

CONTROLLED SUB-PSILOCYBIN (2025 Session)

15 Oct 2024 · Bill Electronically Reproduced 10/15/2024

Crimes: controlled substances; creating, manufacturing, possessing, or using psilocybin or psilocin; allow under certain circumstances. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7404a. (2024 Session)

9 Oct 2024 · Executive Session: 10/09/2024 01:00 pm Legislative Office Building 205-207

Relative to the use of psychedelics for therapeutic purposes. (2024 Session)

6 Sep 2024 · Placed on the Union Calendar, Calendar No. 544.

To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs. (2024 Session)

3 Sep 2024 · Accompanied a study order, see H5018

Concerning the legal use of the plant medicine known as psilocybin for therapeutic, spiritual, and medicinal purposes (2024 Session)

3 Sep 2024 · Accompanied a study order, see H5032

Relative to plant medicine (2024 Session)

30 Jul 2024 · Accompanied a study order, see S2926

Relative to plant medicine (2024 Session)

1 Jul 2024 · In committee: Set, first hearing. Hearing canceled at the request of author.

Controlled substances: psychedelic-assisted therapy. (2024 Session)

1 Jul 2024 · Accompanied a study order, see H4739

Concerning the use of a prescription medicine that contains 3,4-methylenedioxymethamphetamine (MDMA) (2024 Session)

21 May 2024 · Introduced

Allows the growth, cultivation, and regulated adult use of psilocybin for the treatment of certain health conditions; provides for the certification of support service providers and the licensure of cultivators. (2024 Session)

17 May 2024 · Formal Calendar S Bills for Perfection

Modifies provisions relating to alternative therapies and treatments, including psilocybin (2024 Session)

16 May 2024 · May 16 hearing: Held in committee and under submission.

The Regulated Psychedelic Facilitators Act and the Regulated Psychedelic-Assisted Therapy Act. (2024 Session)

16 May 2024 · Signed into Law

Task Force on Responsible Use of Natural Psychedelic Substances (2024 Session)

16 May 2024 · Signed into Law

Task Force on Responsible Use of Natural Psychedelic Substances (2024 Session)

10 May 2024 · CARRIED OVER, in the same posture, to any special session of the 131st Legislature, pursuant to Joint Order HP 1482.

Resolve, to Establish the Commission to Study Pathways for Creating a Psilocybin Services Program in Maine (2024 Session)

10 May 2024 · Enrolled (Passed Both Chambers)

An act relating to the establishment of the Psychedelic Therapy Advisory Working Group (2024 Session)

2 May 2024 · In Committee

Relative to the regulation and taxation of natural psychedelic substances (2024 Session)

2 May 2024 · Introduced

REPORT of the SPECIAL JOINT COMMITTEE on INITIATIVE PETITIONS on the INITIATIVE PETITION of SARKO GERGERIAN AND OTHERS FOR THE PASSAGE OF AN ACT RELATIVE TO THE REGULATION AND TAXATION OF NATURAL PSYCHEDELIC SUBSTANCES (see House, No. 4255) (2024 Session)

16 Apr 2024 · Referred

An Act Concerning The Decriminalization Of Possession Of Small Amounts Of Psilocybin. (2024 Session)

14 Mar 2024 · Introduced

Directs the commissioner of health, in conjunction with the commissioners of mental health and veterans' services, to conduct a study on the use of ibogaine as a treatment for post-traumatic stress disorder, and the increasing rate of PTSD diagnoses in veterans and first responders. (2024 Session)

14 Feb 2024 · Engrossed (Passed One Chamber)

Study Psilocybin For Therapeutic Treatments (2024 Session)

12 Feb 2024 · Accompanied a study order, see S2642

Regulating the safe use of psilocybin (2024 Session)

8 Feb 2024 · PRINT NUMBER 7832A

Establishes the psilocybin assisted therapy pilot program; provides such program will be offered to ten thousand veterans and first responders from the western region of New York state. (2024 Session)

1 Feb 2024 · Committee recommended measure be held for further study

Amends the current law on controlled substances to permit a person to be in possession of less than one ounce of psilocybin and permits psilocybin to be securely cultivated within a person's residence for personal use. (2024 Session)

16 Jan 2024 · print number 8349a

Establishes the psilocybin assisted therapy pilot program; provides such program will be offered to ten thousand veterans and first responders from the western region of New York state. (2024 Session)

10 Jan 2024 · Introduced

Concerning psilocybin services. (2024 Session)

8 Jan 2024 · Introduced

Concerning psilocybin services. (2024 Session)

3 Jan 2024 · Referred

Requires the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction. (2024 Session)

3 Jan 2024 · Referred

Requires the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction. (2024 Session)

3 Jan 2024 · Referred

Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor. (2024 Session)

3 Jan 2024 · Referred

Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor. (2024 Session)

11 Dec 2023 · Carried over to 2024 Regular Session.

Relating To Psilocybin. (2023 Session)

11 Dec 2023 · Carried over to 2024 Regular Session.

Relating To Psilocybin. (2023 Session)

14 Sep 2023 · Introduced

Controlled substances: penalties; conduct associated with entheogenic plants and fungi; exempt from criminal penalties in certain circumstances. Amends secs. 7401, 7403 & 7404 of 1978 PA 368 (MCL 333.7401 et seq.). (2023 Session)

23 Jul 2023 · Effective date 7/23/2023*.

Concerning access to psilocybin services by individuals 21 years of age and older. (2023 Session)

23 Jun 2023 · Referred

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy. (2023 Session)

25 May 2023 · Introduced

Douglas Mike Day Psychedelic Therapy to Save Lives Act of 2023 (2023 Session)

12 May 2023 · Committee Report

An Act Concerning The Decriminalization Of Possession Of Small Amounts Of Psilocybin. (2023 Session)

11 Apr 2023 · Subcommittee recommends passage. Vote Total: 3-0.

A bill for an act removing psilocybin and psilocyn from the list of substances classified as schedule I controlled substances under Iowa's uniform controlled substances Act. (2023 Session)

29 Mar 2023 · Referred

Controlled dangerous substances; authorizing certain scientific research and clinical trials related to psilocybin and psilocyn; requiring registration; providing certain immunities; effective date. (2023 Session)

21 Mar 2023 · Referred

Relating to the establishment of the Psilocybin Research Advisory Council. (2023 Session)

15 Mar 2023 · Referred

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group. (2023 Session)

15 Mar 2023 · Referred

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group. (2023 Session)

15 Mar 2023 · Referred

Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients. (2023 Session)

15 Mar 2023 · Referred

Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients. (2023 Session)

15 Mar 2023 · Referred

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group. (2023 Session)

15 Mar 2023 · Referred

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group. (2023 Session)

15 Mar 2023 · Author added Hudson

Psychedelic medicine task force established, and report required. (2023 Session)

9 Mar 2023 · Inexpedient to Legislate: Motion Adopted DV 274-97 03/09/2023 House Journal 8 P. 27

Exempting dimethyltryptamine from the controlled drug act. (2023 Session)

7 Mar 2023 · Author added Kupec

Psychedelic medicine task force establishment (2023 Session)

3 Mar 2023 · Failed

Psilocybin Recommendation Pilot Program Amendments (2023 Session)

1 Mar 2023 · Committee Report

Study Use Of Psilocybin For Mental Health (2023 Session)

1 Mar 2023 · Introduced

An act relating to decriminalizing certain chemical compounds found in plants and fungi that are commonly used for medicinal, spiritual, religious, or entheogenic purposes (2023 Session)

24 Feb 2023 · Introduced

An act relating to removal of criminal penalties for possessing, dispensing, or selling psilocybin and establishment of the Psychedelic Therapy Advisory Working Group (2023 Session)

14 Feb 2023 · Tabled in Rules (13-Y 5-N)

Virginia Psilocybin Advisory Board; established, report. (2023 Session)

8 Feb 2023 · Change of Reference, Senate to Committee on Appropriations

An Act Concerning The Psychedelic-assisted Therapy Pilot Program. (2023 Session)

7 Feb 2023 · Left in Courts of Justice

Psilocybin; possession or distribution for certain medical purposes permitted, penalty. (2023 Session)

30 Jan 2023 · Referred

Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients. (2023 Session)

30 Jan 2023 · Referred

Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients. (2023 Session)

9 Jan 2023 · Introduced

An Act Allowing The Use Of Psilocybin For Medicinal And Therapeutic Purposes. (2023 Session)

5 Dec 2022 · Introduced

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness; decriminalizes, and expunges past offenses involving, psilocybin production, possession, use, and distribution. (2022 Session)

23 Jun 2022 · Introduced

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness; decriminalizes, and expunges past offenses involving, psilocybin production, possession, use, and distribution. (2022 Session)

8 Jun 2022 · Passed

FDA-approved Prescription 3,4-Methylenedioxymethamphetamine Drug Use (2022 Session)

6 Jun 2022 · Certified copies of resolutions sent, 06/06/22.

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older. (2022 Session)

28 Apr 2022 · Session ended; bill fell without enactment.

Medical Cannabis (Access) Bill (2021–22)

19 Apr 2022 · Committee Report

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Long-term Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older. (2022 Session)

14 Apr 2022 · Coauthored by Representative Pae

Controlled dangerous substances; authorizing certain research and clinical trials related to psilocybin and psilocin; requiring registration; providing certain immunities. (2022 Session)

31 Mar 2022 · Lay HB1349 on Table (Rep. Abbas): Motion Adopted Regular Calendar 210-132 03/31/2022 House Journal 9

Decriminalizing the possession and use of psilocybin mushrooms. (2022 Session)

16 Mar 2022 · Referred

Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients. (2022 Session)

10 Mar 2022 · Referred

Relating To Psilocybin. (2022 Session)

8 Feb 2022 · Referred

Public health; providing for the establishment of statewide investigational new drug applications for psilocybin clinical trials; effective date. (2022 Session)

31 Jan 2022 · Passed by indefinitely in Judiciary (8-Y 6-N 1-A)

Psilocybin or psilocyn; possession, civil penalty. (2022 Session)

28 Jan 2022 · Referred

Relating To Psilocybin. (2022 Session)

8 Oct 2019 · Session ended without enactment.

Legalisation of Cannabis (Medicinal Purposes) Bill (2017–19)

26 May 2016 · Principal provisions commenced under SI 2016/553, insofar as not already in force.

Psychoactive Substances Act 2016 (2015–16)

12 May 2016 · Session ended; no further progress and no enactment.

Cannabis (Legalisation and Regulation) Bill (2015–16)